Abstract
277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-alpha maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was greater than 36 months in stage II and 11 months in stage III patients.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carmustine / administration & dosage
-
Combined Modality Therapy
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Interferon Type I / administration & dosage*
-
Male
-
Melphalan / administration & dosage
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / pathology
-
Multiple Myeloma / therapy*
-
Neoplasm Staging
-
Prednisone / administration & dosage
-
Recombinant Proteins
-
Vincristine / administration & dosage
Substances
-
Interferon Type I
-
Recombinant Proteins
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Melphalan
-
Carmustine
-
Prednisone